Ocugen, Inc. · NASDAQ:OCGN
Ocugen — Q2 2023 Earnings Presentation
14 slides from Ocugen's earnings presentation, Aug 22, 2023
Slide 1: 2Q 2023 Business Update
ocugen. > ee 2Q 2023 Business Update NASDAQ: OCGN
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “ na ne
Slide 3: 2023/2024: Updated Anticipated Timing on Milestones
2023/2024: Updated Anticipated Timing on Milestones 2Q 3Q 4Q 1Q Clinical study results update Initiate Phase 3 trial* ocu400 ) —__ IND submitted: Phase 1/2 trial in dry AMD IND cleared by FDA Initiate Phase 1/2 trial ocu4i0 = © ® IND submitted: Phase 1/2 trial Initiate Phase 1/2 trial IND cleared by
Slide 4: Modifier gene therapy: improved visual outcomes and quality of life
Improved visual outcomes and quality of life GENE X GENE M cell NR2E3 Delivery “Molecular reset” of health & survival gene networks cell Cell with normal function Restored retinal cell homeostasis ONL ONL/photoreceptor survival GENE X Cell with mutated/ nonfunctioning gene(s) other than modifier gen
Slide 5: Nuclear Hormone Receptors (NHRs) as master regulators of genes in the retina
• • • Nuclear Hormone Receptors (NHRs): intracellular receptors that regulate gene expression, acting as a master regulator of genes in the retina.
Slide 6: OCU400: Expected Pathway to Clinical Development & Potential Approval
OCU400: Expected Pathway to Clinical Development & Potential Approval Proposed Broad RP Phase 1/2 Phase 3 Potential approval Indication 2022-2023 ] 2023 - 2025 2025/26 4 Phase 4 Commitments Adult RP a aie a Meee Proposed It ap ‘i 5] RHO Hi rto0 Indication Pediatric toa CEJ cerz90 EI cerzs0 RP &LCA B
Slide 7: OCU410 for the Treatment of Dry Age-related Macular Degeneration (AMD)
OCU410 for the Treatment of Dry Age-related Macular Degeneration (AMD) Targets all four hallmark conditions of dry AMD: lipid metabolism, inflammation, oxidative stress, and complement activation Limited options for AMD, presenting significant unmet medical need * US:10M * Worldwide: condition affec
Slide 8: OCU410ST: Received ODD for ABCA4-Associated Retinopathies
OCU410ST: Received ODD for the Treatment of ABCA4-Associated Retinopathies— Stargardt, Retinitis Pigmentosa 19 (RP19) and Cone-rod Dystrophy 3 (CORD3) ABCA4-associated retinopathies—Genetic Rare Disease * ABCA4 gene produces an ATP-binding cassette (ABC) superfamily transmembrane protein involved in
Slide 9: OCU500 Series: Next-Generation Vaccine Technology
OCUS5O0O Series: Next-Generation Vaccine Technology Inhaled mucosal vaccine platform based on ChAd vector Inhalation technology as a differentiator * Multiple preclinical studies using Ocugen’s vector demonstrated vaccine-induced high neutralizing and effector responses * Clinical studies using a si
Slide 10: Pipeline Updates
Pipeline Updates ocun0o: Teansteran Tumetatin OCU200 * Providing FDA with the requested information related to chemistry, manufacturing and controls to release the clinical hold * Plan to initiate Phase 1 trial in 4Q 2023 NeoCart® ¢« Manufacturing facility construction for NeoCart is on target to be
Slide 11: Financial Update
—— Financial Update
Slide 12: Financial Update
Financial Update Statement of Operations Three months ended June 30, 2023 2022 Research and development expense $14.2" $9.0 General and administrative expense 9.6 10.6 Other income (expense), net 08 O11 Net loss $(22.9) $019.5) Net loss per share of common stock — basic and diluted $(0.10) $(0.09) B
Slide 13: Questions & Answers
Questions & Answers ocugen.
Slide 14: Thank you!